Microsoft Research unveiled Quine, a multimodal biology world model designed to guide experimental design by integrating data across proteins, cells, tissues, and genomes, while offering an interactive layer and orchestration models to assist lab work rather than replace it.

Quine consolidates sequence, structure, function, cellular state, and imaging into a single workflow to enable cross-domain learning and predictions.

The system is experimental and not a clinical product; access is limited to collaborations and a fellowship, with outputs requiring expert review and laboratory validation.

In practice, the workflow accelerated decision-making by narrowing candidates over a single weekend, potentially saving months of lab work and reducing costs.

Experts emphasize that reproducibility by independent researchers on unfamiliar problems with noisy data is the real test, beyond internal demonstrations.

Quine aims to improve experimental design by proposing, ranking, and prioritizing hypotheses for lab testing, while accepting imperfect models that still offer useful guidance.

The first Quine Fellows cohort is open for applications, with a 16-week program in 2027 and potential access to resources, running from mid-2027; applications were open late September to early November 2026.

Progress will be signaled by the 16-week fellows results and published methods, transparent disclosures about the world model and uncertainties, and product integration through Microsoft Discovery after scientific validation.

Quine provides an interactive layer where researchers can access other models, tools, and papers while deciding which questions to pursue and which results to test experimentally.

Overall, Quine represents a proof-of-concept for integrated research that may outperform siloed models in some contexts, but its status, reproducibility, and governance require transparent independent verification.

The system is designed to forecast how biological states change under interventions and to reason through downstream consequences, enabling ranking and prioritization of experiments before wet-lab validation.

Quine has demonstrated success in identifying compounds that shift cancer cells between states, including an unexpected third-state tendency observed in lab tests.